🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being described as a "huge turning point" in the fight against drug-resistant strains of the bacteria, according to scientists.

An International Challenge

Gonorrhoea infections are escalating globally, with data suggesting over 82 million new cases each year. Particularly high rates are observed in Africa and nations within the WHO's designated area, which includes China and Mongolia to New Zealand. In England, cases have reached a historical peak, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune advancement in the reality of growing infection rates, increasing antimicrobial resistance and the highly restricted available drugs at this time.”

Health officials are particularly alarmed about the increase in antibiotic-resistant strains. The WHO has classified it as a "priority pathogen". Recent surveillance found that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Therapies Secure Approval

Zoliflodacin, also known as a brand name, was approved by the US FDA in mid-December for use against gonorrhoea. This disease can lead to significant complications, including infertility. Scientists anticipate that targeted use of this new drug will help slow the development of resistance.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, also received approval in close succession. This medication, which is employed against UTIs, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment emerged from a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to develop it.

“This approval marks a major breakthrough in the therapy of superbug gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Clinical Trial Outcomes and Worldwide Availability

As per results published in a prominent scientific publication, zoliflodacin cured the vast majority of uncomplicated infections. This places it at an equal footing with the existing first-line therapy, which combines an injection and a pill. The study included hundreds of volunteers from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, GARDP has the authority to make available and distribute the drug in numerous regions with limited resources.

Doctors treating patients have expressed optimism. The availability of a one-pill regimen of this kind is hailed as a "game-changer" for public health efforts. This is deemed crucial to alleviate the strain of the infection for individuals and to prevent the spread of extremely resistant gonorrhoea globally.